

## Vitamin B<sub>12</sub>

### DESCRIPTION

The term vitamin B<sub>12</sub> (cobalamin) is used in two different ways. Vitamin B<sub>12</sub>, a member of the B-vitamin family, is a collective term for a group of cobalt-containing compounds known as corrinoids. The principal cobalamins are cyanocobalamin, hydroxocobalamin and the two coenzyme forms of vitamin B<sub>12</sub>, methylcobalamin and 5-deoxyadenosylcobalamin (adenosylcobalamin). The term vitamin B<sub>12</sub> is more commonly used to refer to only one of these forms, cyanocobalamin. Cyanocobalamin is the principal form of the vitamin used for fortification of foods and in nutritional supplements. In this monograph, vitamin B<sub>12</sub> will be used in both ways. The meaning will be clear from its context. The cobalamins are comprised of a nucleotide (base, ribose and phosphate) attached to a corrin ring. The corrin ring is made up of four pyrrole groups and an atom of cobalt in its center. The cobalt atom attaches to a methyl group, a deoxyadenosyl group, a hydroxyl group or a cyano group, to yield the four cobalamin forms mentioned above.

Vitamin B<sub>12</sub> is the most chemically complex of all the vitamins. It is also one of the most biologically interesting ones. Because of the striking dark red color of its crystals, vitamin B<sub>12</sub> has been called "nature's most beautiful cofactor." Its close relatives hemoglobin, chlorophyll and the

cytochromes are also brightly colored complex organometallic substances, which, along with vitamin B<sub>12</sub> and some others derived from the parent molecule called uroporphyrinogen III, have led to their being known as the pigments of life. Vitamin B<sub>12</sub> works in close partnership with folate in the synthesis of the building blocks for DNA and RNA synthesis as well as the synthesis of molecules important for the maintenance of the integrity of the genome. It is also essential for the maintenance of the integrity of the nervous system and for the synthesis of molecules which are involved in fatty acid biosynthesis and the production of energy. The human body does all of this with just two to three milligrams of the vitamin, which is much less than the weight of a tenth of a drop of water. It is even speculated that B<sub>12</sub> was mainly responsible for the origin of the DNA world from the RNA world.

Deficiency of vitamin B<sub>12</sub> results in hematological, neurological and gastrointestinal effects. The hematological effects of the deficiency are identical to that of folate deficiency and are caused by interference with DNA synthesis. The hematologic symptoms and signs of B<sub>12</sub> deficiency, include hypersegmentation of polymorphonuclear leukocytes, macrocytic, hyperchromic erythrocytes, elevated mean corpuscular volume (MCV), elevated mean corpuscular hemoglobin concentration (MCH, MCHC), a decreased red blood cell count, pallor of the skin, decreased energy and easy fatigability, shortness of breath and palpitations. The resulting anemia of B<sub>12</sub> deficiency, as is the case of the anemia of folate deficiency, is a megaloblastic macrocytic anemia. However, in the context of a simultaneous iron deficiency anemia, which is a microcytic one, anemia secondary to B<sub>12</sub> deficiency may not result in macrocytic erythrocytes.

The neurological effects of the vitamin deficiency may occur even in the absence of anemia. This is particularly true in those who are over 60 years old. Vitamin B<sub>12</sub> deficiency principally affects the peripheral nerves, and in later stages, the spinal cord. The symptoms and signs of the neurological effects of B<sub>12</sub> deficiency, include tingling and numbness in the extremities (particularly the lower extremities), loss of vibratory and position sensation, abnormalities of gait, spasticity, Babinski's responses, irritability, depression and cognitive changes (loss of concentration, memory loss, dementia). Visual disturbances, impaired bladder and bowel control, insomnia and impotence may also occur. Gastrointestinal effects of B<sub>12</sub> deficiency, include intermittent diarrhea and constipation, abdominal pain, flatulence and burning of the tongue (glossitis). Anorexia and weight loss are general symptoms of B<sub>12</sub> deficiency. Recently, age-related hearing loss has been associated with poor vitamin B<sub>12</sub> and folate status. Poor B<sub>12</sub> status has also been associated with Alzheimer's disease.

Pernicious anemia is the most common cause of clinical B<sub>12</sub> deficiency in temperate regions. Pernicious anemia is the result of an autoimmune process in which parietal cell autoantibodies against the gastric H<sup>+</sup>/K<sup>+</sup>-adenosine triphosphatase (the gastric proton pump) cause loss of gastric parietal cells. The loss of parietal cells results in diminished production of the intrinsic factor. The intrinsic factor is necessary for B<sub>12</sub> absorption (see Pharmacokinetics). Deficiency of intrinsic factor results in B<sub>12</sub> deficiency. Inadequate B<sub>12</sub> intake is another cause of B<sub>12</sub> deficiency. Breastfed infants of vegan mothers are particularly at risk for B<sub>12</sub> deficiency. Total gastrectomy results in B<sub>12</sub> deficiency secondary to lack of intrinsic factor. Pancreatic insufficiency and atrophic gastritis result in B<sub>12</sub> deficiency secondary to inability to digest dietary protein-bound B<sub>12</sub>. Small bowel disorders, including ileal resection or bypass, Crohn's disease, malignancy, tropical sprue, celiac sprue (gluten-induced enteropathy) and amyloidosis result in B<sub>12</sub> deficiency secondary to decreased absorption of the vitamin. Bacterial overgrowth of the small intestine results in B<sub>12</sub> deficiency secondary to bacterial competition for uptake of the vitamin. Certain drugs, including proton pump inhibitors can interfere with absorption of the vitamin (see Interactions). Nitrous oxide anesthesia can cause a functional B<sub>12</sub> deficiency via degradation of B<sub>12</sub> coenzymes (see Interactions). Rare congenital disorders such as transcobalamin II deficiency and defective intrinsic factor production result in B<sub>12</sub> deficiency. Finally, infestation with the tapeworm *Diphyllobothrium latum* can cause B<sub>12</sub> deficiency secondary to competition for uptake of B<sub>12</sub> by the parasite. In this regard, in the early 1900s, B<sub>12</sub> deficiency was common in Jewish women in the United States who prepared their own gefilte fish. They used fresh-water fish, including pike, pickeral and carp, which hosted the wormlike larvae of the parasite. The women would sample the fish, by tasting it, from the time it was quite raw until it was well cooked. Although their children totally enjoyed the prepared gefilte fish, the Jewish mothers wound up with forty-foot parasites in their digestive tracts and B<sub>12</sub> deficiencies.

The two coenzyme forms of vitamin B<sub>12</sub> are methylcobalamin and 5'-deoxyadenosylcobalamin (adenosylcobalamin). Methylcobalamin is a cofactor for the enzyme methionine synthase, while adenosylcobalamin is a cofactor for the enzyme L-methylmalonyl coenzyme A (methylmalonyl-CoA) mutase. Methionine synthase is one of the key enzymes in intermediary metabolism. It catalyzes the conversion of homocysteine to methionine. Its folate partner in the reaction is 5-methyltetrahydrofolate (intracellular folates are present in their polyglutamate forms). This is the only reaction in the body in which folate and B<sub>12</sub> are coparticipants. In addition to forming methionine, 5-methyltetrahydrofolate is converted to tetrahydrofolate. The reactions

occur in the following manner: methylcobalamin transfers its methyl group to homocysteine yielding methionine and 5-methyltetrahydrofolate transfers its methyl group to cobalamin reconverting it to methylcobalamin. Methionine is converted to S-adenosylmethionine (SAME), the major donor of methyl groups in transmethylation reactions, including reactions that are involved in the synthesis of basic myelin basic protein.

Tetrahydrofolate is converted to 5,10-methylenetetrahydrofolate via the action of the enzyme serine hydroxymethyltransferase. 5,10-Methylenetetrahydrofolate is presented with three metabolic opportunities. It can be converted to 5-methyltetrahydrofolate—the folate cofactor of the methionine synthase reaction—via the enzyme 5,10-methylenetetrahydrofolate reductase; it can transfer its one-carbon residue to deoxyuridylic acid to form thymidylic acid or it can be converted to 5-formyltetrahydrofolate, which is a one-carbon donor in the *de novo* synthesis of purine nucleotides.

The hematological effects of B<sub>12</sub> deficiency are accounted for as follows: B<sub>12</sub> deficiency leads to reduced synthesis of tetrahydrofolate as well as methionine. Decreased tetrahydrofolate results in decreased 5,10-methylenetetrahydrofolate which in turn, results in decreased conversion of deoxyuridylic acid to thymidylic acid and decreased *de novo* synthesis of purine nucleotides. In addition, because of decreased synthesis of methionine and S-adenosylmethionine, the enzyme 5,10-methylenetetrahydrofolate reductase converts most of the 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the so-called methyl trap. To summarize, decreased B<sub>12</sub> results in a decrease in the nucleotide precursor pool for DNA synthesis (thymidylic acid, purine nucleotides) which results in decreased DNA replication and cell division and finally to a megaloblastic anemia. Since the megaloblastic anemia induced by B<sub>12</sub> deficiency is caused by a functional cellular folate deficiency, it is not surprising that it can be corrected with administration of folate. On the other hand, the neurological deficits of vitamin B<sub>12</sub> deficiency can not be corrected with folate administration. Further, high doses of folate administered to those with an undiagnosed B<sub>12</sub> deficiency can cause progression of neurological symptoms.


The neurological effects of B<sub>12</sub> deficiency are accounted for as follows: Consequences of B<sub>12</sub> deficiency, in addition to those mentioned above, include increased serum levels of homocysteine, decreased levels of methionine and S-adenosylmethionine and a decreased ratio of S-adenosylmethionine to S-adenosylhomocysteine, the product of S-adenosylmethionine methyltransferase reactions. Decreased S-adenosylmethionine in the central nervous system results in decreased methylation reactions and an overall state of hypomethylation. Transmethylation reactions are important in the synthesis of a number of substances in the central

nervous system, including myelin basic protein which is involved in the process of myelination. Much research is needed to better elucidate the mechanism of the neurological effects of B<sub>12</sub> deficiency.

In addition to methionine synthase, B<sub>12</sub> is a cofactor in the methylmalonyl-CoA mutase reaction. In this reaction, the coenzyme form of B<sub>12</sub> is adenosylcobalamin. A number of substances, including the branched-chain amino acids isoleucine and valine, as well as methionine, threonine, thymine and odd-chain fatty acids are metabolized via methylmalonyl semialdehyde or propionyl-CoA to methylmalonyl-CoA. Methylmalonyl-CoA mutase converts methylmalonyl-CoA to succinyl-CoA. This occurs in the mitochondria. Succinyl-CoA can be metabolized in the tricarboxylic acid cycle to produce energy and it is also involved in the synthesis of fatty acids. Methylmalonic acid is elevated in the serum and urine in those with B<sub>12</sub> deficiency.

Animal products are the principal food sources of vitamin B<sub>12</sub>. B<sub>12</sub> cannot be made by plants or by animals. It is thought that only bacteria (eubacteria, archaebacteria) manufacture the vitamin. The B<sub>12</sub> in animal products is derived from bacterial B<sub>12</sub> sources. The richest dietary sources of cobalamin are the liver, brain and kidney. Other sources, include egg yolk, clams, oysters, crabs, sardines, salmon and heart. Lower amounts of cobalamin are found in fish, beef, lamb, pork, chicken, cheese and milk. Plant foods are generally devoid of B<sub>12</sub>. Some fermented plant products, e.g., tempeh, may have some vitamin B<sub>12</sub>. Pseudovitamin B<sub>12</sub> refers to B<sub>12</sub>-like substances which are found in certain organisms, such as *Spirulina* spp. (blue-green algae, cyanobacteria). However, these substances do not have B<sub>12</sub> biological activity for humans. Food-form B<sub>12</sub> is comprised of protein-bound methylcobalamin and adenosylcobalamin.

Vitamin B<sub>12</sub>, B<sub>12</sub> and cobalamin are terms that are used interchangeably. Vitamin B<sub>12</sub> most commonly refers to one of the cobalamin forms, cyanocobalamin. Cyanocobalamin is also known as 5,6-dimethylbenzimidazolyl cyanocobamide. Its molecular formula is C<sub>63</sub>H<sub>88</sub>CoN<sub>14</sub>O<sub>14</sub>P and its molecular weight is 1355.38 daltons. The structural formula is:



Vitamin B<sub>12</sub>

#### ACTIONS AND PHARMACOLOGY

##### ACTIONS

Vitamin B<sub>12</sub> is used in the treatment of B<sub>12</sub> deficiency states, including megaloblastic anemia. It may have antiatherogenic, neuroprotective, anticarcinogenic and detoxifying activities. B<sub>12</sub> has putative anti-allergic and mood-modulatory activities.

##### MECHANISM OF ACTION

Vitamin B<sub>12</sub>, in the form of methylcobalamin, is a cofactor in the methionine synthase reaction. The enzyme converts homocysteine to methionine. Folate, in the form of 5-methyltetrahydrofolate (as the pentaglutamate) is the other cofactor in the reaction. In addition to methionine, tetrahydrofolate (again, as the pentaglutamate) is also formed. Tetrahydrofolate is converted to 5,10-methylenetetrahydrofolate which is a cofactor in the formation of thymidylic acid from deoxyuridylic acid and which is also converted to 5-formyltetrahydrofolate, a one-carbon donor in the *de novo* synthesis of purine nucleotides. B<sub>12</sub> deficiency results in decreased formation of thymidylic acid and purine nucleotides, precursors of DNA synthesis and which are necessary for normal cell division. Megaloblastic anemia is the consequence of this and administration of B<sub>12</sub>, which yields the B<sub>12</sub> cofactor for methionine synthase, corrects this problem. Methionine is a precursor of S-adenosylmethionine

(SAME). SAME is the principal transmethyating agent and is involved in, among many other things, the synthesis of myelin basic protein. Abnormal myelin basic protein resulting in defective myelination, is thought to be responsible for many of the neurological effects of B<sub>12</sub> deficiency. The neurological effects may or may not be corrected with administration of B<sub>12</sub> in those with B<sub>12</sub> deficiency. Whether the neurological effects are reversible after treatment depends on their duration.

Hyperhomocysteinemia is thought to be an independent risk factor for coronary heart disease and other vascular disorders. B<sub>12</sub> works in concert with folate in the methionine synthase reaction, which metabolizes homocysteine to methionine. This is a key reaction in the maintenance of low serum homocysteine levels. The mechanism by which elevated homocysteine levels might increase the risk of developing vascular disease is unclear. It has been shown that homocysteine increases platelet adhesiveness, promotes the growth of smooth muscle cells and causes endothelial dysfunction. Homocysteine may also promote oxidative stress resulting in, among other things, the oxidation of low-density lipoproteins (LDL) to oxidized-LDL. All of these possible activities of homocysteine can play roles in atherogenesis.

B<sub>12</sub> deficiency can result in a number of neurological effects, including peripheral neuropathy and cognitive changes, including memory loss and dementia. Administration of B<sub>12</sub> successfully reverses mild memory impairment and peripheral neuropathy, if not advanced neurological deficits, in most elderly subjects deficient in the vitamin. The mechanism by which B<sub>12</sub> deficiency causes neurological effects and by which B<sub>12</sub> administration may reverse them is not well understood. B<sub>12</sub> and folate are cofactors in the conversion of homocysteine to methionine and methionine is the precursor of the transmethyating agent S-adenosylmethionine (SAME). SAME is involved in the synthesis of myelin basic protein which can become defective in the context of B<sub>12</sub> deficiency. Defective myelin basic protein and resultant defective myelination can account, in large part, for the peripheral neuropathy of B<sub>12</sub> deficiency. Hyperhomocysteinemia, another consequence of B<sub>12</sub> deficiency, may also contribute to the neurological effects of deficiency of the vitamin. Elevated homocysteine levels may cause cerebrovascular effects which could lead to cognitive changes. Decreased brain levels of SAME may result in disturbances in certain neurotransmitters. SAME is involved in key methylation reactions in catecholamine synthesis and metabolism in the brain. These neurotransmitters are known to be important in maintaining the affective state. In the elderly, depression often presents as cognitive changes, including dementia.

Vitamin B<sub>12</sub> deficiency has been associated with Alzheimer's disease, at least in some with this neurodegenerative disorder. It is hypothesized that the altered B<sub>12</sub> status that may occur in those with the disorder is due, in part, to a defect in the protein megalin. Megalin is a member of the low-density lipoprotein receptor family, and mediates the ileal uptake of the cubulin-bound B<sub>12</sub>-intrinsic factor complex (see Pharmacokinetics). The low-density lipoprotein receptors include receptors that bind apolipoprotein E, amyloid precursor protein and alpha<sub>2</sub>-macroglobulin, substances that have been linked to Alzheimer's disease. Impaired transport of B<sub>12</sub> to the central nervous system may, in part, account for the pathogenesis of the disorder.

There is some evidence, mainly epidemiological, that B<sub>12</sub> may protect against certain types of cancer. A couple of clinical studies have shown that a combination of B<sub>12</sub> and folic acid significantly reduces the number of abnormal bronchial cells thought to be cancer cell precursors. The mechanism of the possible anticarcinogenic effect of B<sub>12</sub> is unclear. B<sub>12</sub> deficiency results in decreased levels of SAME and thymidylic acid, as discussed above. SAME, among other things, is involved in DNA methylation which results in regulation of its genetic expression via a process known as gene silencing. Abnormal DNA methylation patterns are characteristic of neoplastic cells. Decreased SAME and thymidylic acid levels may also lead to increased errors in DNA replication, increased DNA strand breaks and defective DNA repair.

Hydroxocobalamin is used in conditions which are associated with cyanide toxicity, such as may occur with sodium nitroprusside therapy and Leber's optic atrophy. Hydroxocobalamin is used parenterally in these cases; it combines with cyanide to form cyanocobalamin. Clearly, cyanocobalamin is not the right form of B<sub>12</sub> for use in these conditions. B<sub>12</sub> can also combine with sulfite and has been found to be effective in the management of sulfite-induced hypersensitivity conditions in some preliminary studies. The studies used cyanocobalamin. Perhaps better results could have been obtained with hydroxocobalamin. There is no evidence that B<sub>12</sub> has any effect in the management of other hypersensitive or allergic conditions.

Vitamin B<sub>12</sub> may have mood-modulatory activity in some, e.g., the elderly, who are B<sub>12</sub> deficient. There is no evidence that B<sub>12</sub> has mood-modulatory activity in those who are not deficient in the vitamin. As discussed above, SAME is involved in key methylation reactions in catecholamine synthesis in the brain and these neurotransmitters are known to be important in maintaining the affective state.

**PHARMACOKINETICS**

Vitamin B<sub>12</sub> is found naturally in food sources (principally animal products) in protein-bound forms. Cyanocobalamin is the principal form of vitamin B<sub>12</sub> used in nutritional supplements and for fortification of foods. Methylcobalamin is also available for nutritional supplementation and hydroxocobalamin is available for parenteral administration.

Naturally found B<sub>12</sub> is dissociated from proteins in the stomach via the action of acid and the enzyme pepsin. The forms of B<sub>12</sub> released by this process are methylcobalamin and adenosylcobalamin. All forms of B<sub>12</sub> bind to proteins called haptocorrins or R proteins, which are secreted by the salivary glands and the gastric mucosa. This binding occurs in the stomach. Pancreatic proteases partially degrade the B<sub>12</sub>-haptocorrin complexes in the small intestine where the B<sub>12</sub> that is released then binds to intrinsic factor (IF). Intrinsic factor is a glycoprotein which is secreted by gastric parietal cells. The B<sub>12</sub>-intrinsic factor complex is absorbed from the terminal ileum into the ileal enterocytes via a process that first requires the complex to bind to a receptor called cubilin. Within the enterocytes, B<sub>12</sub> is released from the B<sub>12</sub>-IF complex and then binds to another protein called transcobalamin II which delivers it to the portal circulation. The portal circulation transports B<sub>12</sub> to the liver which takes up about 50% of the vitamin; the remainder is transported to the other tissues of the body via the systemic circulation.

Vitamin B<sub>12</sub> in the circulation is bound to the plasma proteins transcobalamin I (TCI), transcobalamin II (TCII) and transcobalamin III (TCIII). Approximately 80% of plasma B<sub>12</sub> is bound to TCI. TCII is the principal B<sub>12</sub> binding protein for the delivery of B<sub>12</sub> to cells, via specific receptors for TCII. This B<sub>12</sub> binding protein (TCII) is identical to the one that delivers B<sub>12</sub> from the enterocytes to the portal circulation (see above).

Total absorption increases with increased intake of the vitamin. However, the absorption efficacy of the vitamin decreases with increased dosage. Studies with cyanocobalamin found that 50% of the vitamin was absorbed at a dose of one microgram, 20% at a dose of 5 micrograms and about 5% at a dose of 25 micrograms. Significantly, very large doses of B<sub>12</sub> are absorbed with an absorption efficiency of about one percent. This occurs via passive diffusion even in the absence of intrinsic factor. Thus, large oral doses may be given for the treatment of B<sub>12</sub> deficiency instead of using the parenteral route (usually, intramuscularly). There are now several studies confirming this. The absorption efficiency of B<sub>12</sub> from foods is approximately 50%.

The vitamin B<sub>12</sub>-transcobalamin II complex is degraded intracellularly via lysosomal proteases to yield cobalamin (cyanocobalamin, methylcobalamin, adenosylcobalamin, hy-

droxocobalamin). Cobalamin is metabolized to methylcobalamin in the cytosol and to adenosylcobalamin in the mitochondria. Methylcobalamin is the principal circulating form of cobalamin. Adenosylcobalamin comprises more than 70% of cobalamin in the liver, erythrocytes, kidney and brain. The total body content of cobalamin ranges from two to three milligrams, with approximately 50% of it residing in the liver.

Vitamin B<sub>12</sub> is secreted in the bile and reabsorbed via the enterohepatic circulation. Some of the B<sub>12</sub> secreted in the bile is excreted in the feces. Also, oral B<sub>12</sub> that is not absorbed is excreted in the feces. Reabsorption of B<sub>12</sub> via the enterohepatic circulation requires the intrinsic factor. If the circulating level of B<sub>12</sub> exceeds the B<sub>12</sub> binding capacity of the blood, a situation that usually occurs following parenteral administration of the vitamin, the excess is excreted in the urine.

**INDICATIONS AND USAGE**

Vitamin B<sub>12</sub> is of such vital nutritional importance that some authorities have recently called for mandatory fortification of some foods with this vitamin. Vitamin B<sub>12</sub> is indicated in those with vitamin B<sub>12</sub> deficiency. It is especially important for the elderly and for those who have had gastric surgery. Both groups are at high risk for vitamin B<sub>12</sub> deficiency. There is evidence that it may be beneficial in some others with low vitamin B<sub>12</sub> status and in some with malabsorption of B<sub>12</sub>, including some who are chronically ill, as well as some vegetarians, among others. There is some preliminary indication that vitamin B<sub>12</sub> may be helpful in inhibiting a pre-cancerous condition in the lungs of smokers, that it might help ameliorate the symptoms of some neuropsychiatric disorders and that it might be useful in some with chronic fatigue and HIV disease. It has been suggested that vitamin B<sub>12</sub> might help prevent some vascular diseases and breast cancer, based upon epidemiological and theoretical considerations. Claims that it is a general "energizer" are anecdotal. There is some evidence that vitamin B<sub>12</sub> can protect against hypersensitivity to sulfites. Earlier open trials suggested that methylcobalamin was effective in the management of sleep-wake rhythm disorders. However, a recent double-blind controlled trial with this form of B<sub>12</sub> failed to confirm this. A recent study has associated low vitamin B<sub>12</sub> status with brain atrophy/shrinkage and subsequent cognitive impairment in the elderly.

**RESEARCH SUMMARY**

Clinically, overt vitamin B<sub>12</sub> deficiency manifests as megaloblastic anemia and neurologic dysfunction. There are more clinically silent and subtle forms of cobalamin deficiency which are also reversible with vitamin B<sub>12</sub> therapy. In addition, mild deficiency may be present in a number of populations, including, most significantly, the elderly. It is

estimated that 10-15% of those over 60 have vitamin B<sub>12</sub> deficiency, due, principally, to decreased absorption of naturally occurring vitamin B<sub>12</sub> caused by an age-related atrophic gastritis that diminishes the acid-pepsin secretions that normally release free vitamin B<sub>12</sub> from food proteins.

An editorial in the *American Journal of Clinical Nutrition* recently suggested that the time may be fast approaching when mandatory fortification of some foods with vitamin B<sub>12</sub> will be deemed appropriate. The editorialists note that data from the U.S. National Health and Nutrition Examination Survey (NHANES) "indicate that the function of vitamin B<sub>12</sub> deteriorates as serum folate status increases in persons who are deficient in vitamin B<sub>12</sub>. More seriously, the data show that persons with both low vitamin B<sub>12</sub> and high folate concentrations were at particularly high risk of memory impairment and anemia." Thus a very significant proportion of the elderly could be at high risk of cognitive impairment because of an imbalance between folate and vitamin B<sub>12</sub>. This is of special concern because since 1998 mandatory folic acid fortification has been in effect in the United States, Canada and more than 50 other countries, largely for the purpose of reducing the incidence of neural tube defects in the unborn. Folate fortification is useful, but if it creates a harmful imbalance with respect to vitamin B<sub>12</sub>, the editorialists argue, then the need for concurrent mandatory vitamin B<sub>12</sub> fortification becomes more urgent. They also point out that whereas neural tube defects are a relatively rare event in pregnancies (1 per 1,000), the negative sequelae of vitamin B<sub>12</sub> deficiency are comparatively enormous, including not only increased cognitive dysfunction but also increased incidence of anemia, breast cancer and possibly diabetes in the offspring, among others. There is also the problem, they point out, that folic acid can mask vitamin B<sub>12</sub> deficiency by preventing anemia but not neurological damage. Irrespective of folic acid fortification, they suggest that vitamin B<sub>12</sub> fortification will benefit vegetarians, breastfed infants and the elderly, all of whom are at high risk for deficiencies. So why not do this right now, they ask? And they answer by suggesting that the following investigations first be undertaken:

- 1) Dose-response studies in persons with low vitamin B<sub>12</sub> status due to food-cobalamin malabsorption, the most common cause of low cobalamin status in the elderly.
- 2) Evidence of benefit from randomized trials using low-dose vitamin B<sub>12</sub> with clinical outcomes; current trial evidence, even from high-dose trials, is far from unequivocal.
- 3) Evidence of a lack of adverse effects in large-scale trials; thus far, studies have not been designed to assess such effects. Observational studies that have reported an associa-

tion of B<sub>12</sub> status or intake with an increased risk of cancer should not be ignored.

- 4) Cyanocobalamin is rather unstable and may form cobalamin analogues that interfere with normal cobalamin metabolism and transport.
- 5) Before fortification is introduced, a coherent plan should be developed to document changes in vitamin B<sub>12</sub> status; to monitor the effects on NTD births, on cognition, and anemia in the elderly; and to assess the possible occurrence of untoward effects on the population.
- 6) While waiting for a decision on vitamin B<sub>12</sub> fortification, authorities urgently need to consider how to manage the newly discovered large-scale problem of those with low vitamin B<sub>12</sub> status and high folate status in countries that have fortified with folic acid.

All of this takes on added urgency in view of an important recent study in which an association was made between low vitamin B<sub>12</sub> status and rate of brain volume loss/shrinkage in the elderly. This was a prospective study of 107 community-dwelling volunteers aged 61 to 87 without cognitive impairment at enrollment. The subjects were evaluated annually for five years by clinical examination, MRI scans and cognitive tests. The association observed remained significant after adjustment for age, sex, initial brain volume and several other relevant variables. Confidence in the result was boosted by the fact that this study measured markers of vitamin B<sub>12</sub> status more sensitive than those used in previous studies, most of which merely measured total plasma vitamin B<sub>12</sub>. The researchers hypothesized that vitamin B<sub>12</sub> might help diminish inflammation in the brain and help preserve the integrity of brain myelin. Larger trials are needed to further confirm and expand these findings.

Neurologic symptoms of vitamin B<sub>12</sub> deficiency can occur, contrary to what was previously believed, in the absence of predecessor hematologic abnormalities. Among neurologic abnormalities noted are those involving the spinal cord, peripheral nerves, optic nerves and cerebrum. Sensory disturbances, such as paresthesias in the extremities, are considerably more common than motor disturbances. Neuropathies and myelopathies can occur alone or in combination. Cognitive impairment and mood changes are more common than dementia, psychosis, paranoia and violent behavior. There are rare instances of visual impairment. Age-related hearing loss has been associated with B<sub>12</sub> and folate deficiency in the elderly. Researchers stress the need for prompt treatment. These conditions, if left untreated, often become irreversible.

Those with mild deficiency usually suffer only from neuropathy and modest memory impairment. Some immuno-

logic deficits are also sometimes noted, but it is not known if these are caused by the deficiency. Supplemental vitamin B<sub>12</sub> successfully reverses mild memory impairment and neuropathy in most elderly subjects deficient in this vitamin.

The Food and Nutrition Board has recommended that elderly people obtain 2.4 micrograms of vitamin B<sub>12</sub> daily—from verifiable sources, e.g., either from eating fortified foods, such as cereals, that clearly identify the amount of vitamin B<sub>12</sub> per serving and/or from vitamin B<sub>12</sub> supplements. And some researchers, again noting the danger of irreversibility of neurologic symptoms that go untreated, have recently recommended regular periodic screening of the elderly for detection of vitamin B<sub>12</sub> deficiency at an early stage.

A high prevalence of vitamin B<sub>12</sub> deficiency has also been reported in those who have had gastric surgery. A recent study detected this deficiency in 31% of those who had undergone this type of surgery, compared with 2% of controls of similar age and race. Previous studies had noted an incidence of vitamin B<sub>12</sub> deficiency of 1%-20% in gastric surgery patients, but the most recent study used more metabolic variables to detect the deficiency and tested an older patient sample. It also looked for the deficiency over a longer period of time. Median age of subjects in this study was 67 years.

These researchers found that vitamin B<sub>12</sub> deficiency is often undetected in post-gastric surgery patients whose subsequent neurologic symptoms are often misdiagnosed. Most had not been advised, after surgery, to be monitored for vitamin B<sub>12</sub> deficiency. These researchers stress the need for regular vitamin B<sub>12</sub> screening in all gastric surgery patients, no matter how many years elapsed since the surgery. They point out that vitamin B<sub>12</sub> deficiency may develop many years after surgery.

Vitamin B<sub>12</sub> deficiencies have been reported in some chronically ill populations. Vitamin B<sub>12</sub> has been found to be malabsorbed in some with HIV disease. There have also been reports of vitamin B<sub>12</sub> deficiency in individuals with chronic fatigue of various etiologies. There are anecdotal reports that supplemental vitamin B<sub>12</sub> is helpful in these disorders. Controlled trials are lacking.

Two placebo-controlled trials have shown that a combination of vitamin B<sub>12</sub> and folic acid inhibited a precursor of bronchial squamous cell cancer of the lung in humans. In one of these studies, supplementation with 10 milligrams of folic acid daily, combined with 500 micrograms of vitamin B<sub>12</sub> daily, for four months, produced a significant reduction in the number of subjects, all heavy smokers, who exhibited the abnormal bronchial cells said to be cancer precursors.

Many researchers have noted that diminished vitamin B<sub>12</sub> status is strongly associated with hyperhomocysteinemia, a significant risk factor for cardiovascular disease. Two researchers have noted that, "although folate deficiency is a far more common cause of elevated homocysteine levels than are vitamin B<sub>12</sub> and vitamin B<sub>6</sub> deficiencies, an elevated homocysteine value in an older person should not be considered due to folate deficiency alone. Because elderly people may have elevated homocysteine levels due to vitamin B<sub>12</sub> deficiency, lowering serum total homocysteine levels to reduce the high incidence of vascular disease among the elderly by supplying adequate amounts of all three vitamins may become an important public health issue."

Recently, diminished vitamin B<sub>12</sub> status has been identified as an additional nutritional risk factor for breast cancer among post-menopausal women. This preliminary finding needs follow-up before its significance, if any, can be assessed.

Claims that vitamin B<sub>12</sub> can enhance exercise performance and that it is an "energizer" have not been tested and are based upon anecdotal accounts.

There is evidence that some who are on strict vegetarian or macrobiotic diets may need supplemental vitamin B<sub>12</sub>. Children and the elderly who are on these diets may, in particular, have need of this supplementation. Some have claimed that miso, tamari, tempeh and other soy products can provide adequate B<sub>12</sub> in the absence of meats and dairy products. This has not been demonstrated. Nor has the claim that adequate B<sub>12</sub> can be obtained from spirulina, sea weeds and other sea vegetables. Even unpasteurized miso, claimed to be an excellent source of B<sub>12</sub>, appears to have very little to none of the vitamin. Nor can vegetarians get adequate B<sub>12</sub> from brewer's yeast, grains, cereals or mushrooms. Some sea vegetables are said to contain significant amounts of vitamin B<sub>12</sub>, but accumulating evidence suggests that, instead, these foods contain vitamin B<sub>12</sub> analogues (pseudovitamin B<sub>12</sub>) that do not confer the functions and protection of vitamin B<sub>12</sub> itself.

Again, vitamin B<sub>12</sub> supplementation is highly advised for vegetarians, especially children who are vegetarians. Vegetarians whose diets allow for the regular use of eggs and dairy products can generally obtain enough vitamin B<sub>12</sub> from their diets. Vegetarians consume certain foods (garlic, onions) that contain certain substances (e.g., inulins) which stimulate the growth of certain bacteria (e.g., *lactobacillus*) in the colon. These bacteria produce B<sub>12</sub> and may supply some of the vitamin to the body. However, this needs to be proven.

Finally, there is evidence that vitamin B<sub>12</sub> can protect some from allergy to the sulfites that are added to some foods and wines. In one study, 2,000 micrograms of sublingual vitamin B<sub>12</sub> significantly prevented reactions to sulfites in 17 of 18 sulfite-sensitive subjects challenged with sulfites. Subsequent placebo-controlled trials confirmed this protective effect.

#### CONTRAINDICATIONS, PRECAUTIONS, ADVERSE REACTIONS

##### CONTRAINDICATIONS

Vitamin B<sub>12</sub> (cyanocobalamin, hydroxocobalamin, methylcobalamin) is contraindicated in those hypersensitive to any component of a vitamin B<sub>12</sub>-containing product.

##### PRECAUTIONS

The use of vitamin B<sub>12</sub> to treat vitamin B<sub>12</sub> deficiency or to treat any medical condition requires medical supervision.

Cyanocobalamin should not be used in those with Leber's optic atrophy. This is a congenital disorder associated with chronic cyanide intoxication (e.g., from tobacco smoke). Decreased levels of B<sub>12</sub> have been associated with reduced ability to detoxify the cyanide in exposed individuals and cyanocobalamin may increase the risk of irreversible neurological damage from optic atrophy in those affected with the disorder. Hydroxocobalamin can aid in the detoxification of cyanide. This form of B<sub>12</sub> is an acceptable form for B<sub>12</sub> supplementation in those with this disorder.

A typical dose of B<sub>12</sub> (cyanocobalamin) in nutritional supplements used by pregnant women and nursing mothers is 12 micrograms daily. Pregnant women and nursing mothers should only use doses higher than this if recommended by their physicians.

Administration of doses of vitamin B<sub>12</sub> greater than 10 micrograms daily may produce a hematological response in those with anemia secondary to folate deficiency.

##### ADVERSE REACTIONS

Oral vitamin B<sub>12</sub> is well tolerated even at high doses. There are occasional reports of hypersensitivity reactions (urticaria, rash, pruritus) in those receiving parenteral B<sub>12</sub>. Those who have experienced hypersensitivity reactions from use of parenteral B<sub>12</sub> may experience similar reactions from oral B<sub>12</sub>, although there are very few reports of this occurring.

##### INTERACTIONS

###### DRUGS

**Antibiotics:** The use of antibiotics may alter the intestinal microflora and may decrease the possible contribution of B<sub>12</sub> by certain inhabitants of the microflora (e.g., *Lactobacillus* species) to the body's requirement for the vitamin. This may particularly be a problem for vegetarians. Garlic, onions; leeks, bananas, asparagus and artichokes, among other vegetables and fruits, contain inulins which promote the

growth of certain colonic bacteria, including *Lactobacillus* species (see Inulins).

**Cholestyramine:** Cholestyramine may decrease the enterohepatic reabsorption of B<sub>12</sub>.

**Colchicine:** Colchicine may cause decreased absorption of B<sub>12</sub>.

**Colestipol:** Colestipol may decrease the enterohepatic reabsorption of B<sub>12</sub>.

**H<sub>2</sub> blockers (cimetidine, famotidine, nizatidine, ranitidine):** Chronic use of H<sub>2</sub> blockers may result in decreased absorption of vitamin B<sub>12</sub> naturally found in food sources. They are unlikely to affect the absorption of supplemental B<sub>12</sub>.

**Metformin:** Metformin may decrease the absorption of vitamin B<sub>12</sub>. This possible effect may be reversed with oral calcium supplementation.

**Nitrous oxide:** Inhalation of the anesthetic agent nitrous oxide (not to be confused with nitric oxide) can produce a functional vitamin B<sub>12</sub> deficiency. Nitrous oxide forms a complex with cobalt in methylcobalamin, the cofactor for methionine synthase, resulting in inactivation of the enzyme.

**Para-aminosalicylic acid:** Chronic use of the anti-tuberculosis drug may decrease the absorption of B<sub>12</sub>.

**Potassium chloride:** It has been reported that potassium chloride may decrease the absorption of dietary B<sub>12</sub> in some.

**Proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole):** Chronic use of proton pump inhibitors may result in decreased absorption of vitamin B<sub>12</sub> naturally found in food sources. They are unlikely to affect the absorption of supplemental B<sub>12</sub>.

##### NUTRITIONAL SUPPLEMENTS

**Calcium:** Calcium supplementation may reverse the possible metformin-induced decrease of B<sub>12</sub> absorption.

**Folate:** Folic acid may work synergistically with vitamin B<sub>12</sub> in lowering homocysteine levels.

**Vitamin B<sub>6</sub>:** Vitamin B<sub>6</sub> may work synergistically with vitamin B<sub>12</sub> and folate in lowering homocysteine levels.

**Vitamin C:** Low serum B<sub>12</sub> levels reported in those receiving large doses of vitamin C were artifacts of the effect of ascorbate on the radioisotope assay for B<sub>12</sub>. There are no known interactions between vitamin C and vitamin B<sub>12</sub>.

##### OVERDOSAGE

There are no reports of vitamin B<sub>12</sub> overdosage in the literature.

**DOSE AND ADMINISTRATION**

The principal form of B<sub>12</sub> used in nutritional supplements is cyanocobalamin. Methylcobalamin is also available for nutritional supplementation. Hydroxocobalamin is presently only available for parenteral use.

Cyanocobalamin is available as a single ingredient product and in multivitamin, multivitamin/multimineral and B complex products. Lozenges of cyanocobalamin and methylcobalamin are also available. Prenatal and postnatal vitamin/mineral formulas typically deliver a dose of 12 micrograms of B<sub>12</sub> daily. A general range of B<sub>12</sub> dosage is 3 to 30 micrograms daily. Some use much higher doses. Absorption of naturally occurring B<sub>12</sub> decreases with age. Because of this, the Food and Nutrition Board advises that those older than 50 years should consume foods fortified with B<sub>12</sub> or take a vitamin B<sub>12</sub>-containing nutritional supplement in order to meet the RDA (2.4 micrograms daily).

Those with B<sub>12</sub> deficiency may be managed with high doses of oral B<sub>12</sub>. However, this requires prescription and management by a physician.

The Food and Nutrition Board of the Institute of Medicine of the National Academy of Sciences has recommended the following Dietary Reference Intakes (RDI) for vitamin B<sub>12</sub>:

Infants	Adequate Intakes (AI)
0 through 6 months	0.4 micrograms/day ~ 0.05 micrograms/Kg
7 through 12 months	0.5 micrograms/day ~ 0.05 micrograms/Kg
Children	Recommended Dietary Allowance (RDA)
1 through 3 years	0.9 micrograms/day
4 through 8 years	1.2 micrograms/day
Boys	
9 through 13 years	1.8 micrograms/day
14 through 18 years	2.4 micrograms/day
Girls	
9 through 13 years	1.8 micrograms/day
14 through 18 years	2.4 micrograms/day
Men	
19 years and older	2.4 micrograms/day
Women	
19 years and older	2.4 micrograms/day
Pregnancy	
14 through 50 years	2.6 micrograms/day
Lactation	
14 through 50 years	2.8 micrograms/day

The DV (Daily Value) for vitamin B<sub>12</sub> (cobalamin), which is used for determining the percentage of nutrient daily values on nutritional supplement and food labels, is 6 micrograms. This is based on the U.S. RDA for vitamin B<sub>6</sub>.

**LITERATURE**

- Adachi S, Kawamoto T, Otsuka M, et al. Enteral vitamin B<sub>12</sub> supplements reverse postgastroctomy B<sub>12</sub> deficiency. *Ann Surg.* 2000;232:199-201.
- Baik HW, Russell RM. Vitamin B<sub>12</sub> deficiency in the elderly. *Annu Rev Nutr.* 1999;19:357-377.
- Battersby AR. How nature builds the pigments of life: The conquest of vitamin B<sub>12</sub>. *Science.* 1994;264:1551-1557.
- Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B<sub>12</sub> malabsorption induced by metformin. *Diabetes Care.* 2000;23:1227-1231.
- Bottiglieri T. Folate, vitamin B<sub>12</sub>, and neuropsychiatric disorders. *Nutr Rev.* 1996;54:382-390.
- Butzkueven H, King JO. Nitrous oxide myelopathy in an abuser of whipped cream bulbs. *J Clin Neurosci.* 2000;7:73-75.
- Carmel R. Subtle cobalamin deficiency. *Ann Intern Med.* 1996;124:338-339.
- Carmel R, Gott PS, Waters CH, et al. The frequency of low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. *Eur J Haematol.* 1995;54:245-253.
- Choi S-W. Vitamin B<sub>12</sub> deficiency: A new risk factor for breast cancer? *Nutr Rev.* 1999;57:250-253.
- Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B<sub>12</sub>, and serum total homocysteine levels in confirmed Alzheimer's disease. *Arch Neurol.* 1998;55:1449-1455.
- Dagnelie PC, van Staveren WA, van den Berg H. Vitamin B<sub>12</sub> from algae appears not to be bioavailable. *Am J Clin Nutr.* 1991;53:695-697.
- Delpre G, Stark P, Niv Y. Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. *Lancet.* 1999;354:740-741.
- Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998:306-356.
- Drennan CL, Huang S, Drummond JT, et al. How a protein binds B<sub>12</sub>: A 3.0 Å X-ray structure of B<sub>12</sub>-binding domains of methionine synthase. *Science.* 1994;266:1669-1674.
- Elia M. Oral or parenteral therapy for B<sub>12</sub> deficiency (commentary). *Lancet.* 1998;352:1721-1722.
- Ellenbogen L. Vitamin B<sub>12</sub>. In: Machlin LJ, ed. *Handbook of Vitamins.* New York, NY: Marcel Dekker, Inc; 1984:497-547.
- Farquharson J, Adams JF. Conversion of hydroxo(aquo)cobalamin to sulfitecobalamin in the absence of light: a reaction of importance in the identification of the forms of vitamin B<sub>12</sub>,

- with possible clinical significance. *Am J Clin Nutr.* 1977;30:1617-1622.
- Fata FT, Herzlich BC, Schiffman G, et al. Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B<sub>12</sub> levels. *Ann Intern Med.* 1996;124:299-304.
- Funada U, Wada M, Kawata T, et al. Changes in CD4+CD8+/CD4-CD8+ ratio and humoral immune functions in vitamin B<sub>12</sub>-deficient rats. *Int J Vitam Nutr Res.* 2000;70:167-171.
- Harriman GR, Smith PD, Horne MK, et al. Vitamin B<sub>12</sub> malabsorption in patients with acquired immunodeficiency syndrome. *Arch Intern Med.* 1989;149:2039-2041.
- Hazra A, Kraft P, Selhub J, et al. Common variants of FUT2 are associated with plasma vitamin B(12) levels. *Nat Genet.* 2008;40(10):1160-1162.
- Heimbarger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B<sub>12</sub>. Report of a preliminary randomized, double-blind intervention trial. *JAMA.* 1988;259:1525-1530.
- Higginbottom MC, Sweetman L, Nyhan WL. A syndrome of methylmalonic aciduria, homocystinuria, megaloblastic anemia and neurological abnormalities in a vitamin B<sub>12</sub>-deficient breast-fed infant of a strict vegetarian. *N Engl J Med.* 1978;299:317-323.
- Houeto P, Hoffman JR, Imbert M, et al. Relation of blood cyanide to plasma cyanocobalamin concentration after a fixed dose of hydroxycobalamin in cyanide poisoning. *Lancet.* 1995;346:605-608.
- Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B<sub>12</sub>, and folate in elderly women. *Am J Clin Nutr.* 1999;69:564-571.
- Jacobsen DW, Simon RA, Singh M. Sulfite oxidase deficiency and cobalamin protection in sulfite sensitive asthmatics. *J Allergy Clin Immunol.* 1984;73(Suppl):135.
- Kaptaan K, Beyan C, Ural AU, et al. Helicobacter pylori—is it a novel causative agent in Vitamin B<sub>12</sub> deficiency? *Arch Int Med.* 2000;160:1349-1353.
- Kozyraki R, Fyfe J, Kristiansen M, et al. The intrinsic factor-vitamin B<sub>12</sub> receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. *Nat Med.* 1999;5:656-661.
- Kristiansen M, Kozyraki R, Jacobsen C, et al. Molecular dissection of the intrinsic factor-vitamin B<sub>12</sub> receptor, cubilin, discloses regions important for membrane association and ligand binding. *J Biol Chem.* 1999;274:20540-20544.
- Kuzuminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood.* 1998;92:1191-1198.
- Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther.* 2000;14:651-668.
- Langdon FW. Nervous and mental manifestations of pernicious anemia. *JAMA.* 1905;45:1635-1638.
- Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. *N Engl J Med.* 1988;318:1720-1728.
- Lindstedt G. [Nitrous oxide can cause cobalamin deficiency. Vitamin B<sub>12</sub> is a simple and cheap remedy]. [Article in Swedish]. *Lakartidningen.* 1999;96:4801-4805.
- McCaddon A, Kelly CL. Familial Alzheimer's disease and vitamin B<sub>12</sub> deficiency. *Age Ageing.* 1994;23:334-337.
- Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B<sub>12</sub>) handling. Implications for therapy. *Drugs Aging.* 1998;12:277-292.
- Okawa M, Takahashi K, Egashira K, et al. Vitamin B<sub>12</sub> treatment for delayed sleep phase syndrome. *Psychiatry Clin Neurosci.* 1997;51:275-279.
- Ostreicher DS. Vitamin B<sub>12</sub> supplements as protection against nitrous oxide inhalation. *NY State Dent J.* 1994;60:47-49.
- Refsum H, Smith AD. Are we ready for mandatory fortification with vitamin B-12? *Am J Clin Nutr.* 2008;88(2):253-254.
- Robertson J, Iemolo F, Stabler SP, et al. Vitamin B<sub>12</sub>, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. *CMAJ.* 2005;172(12):1569-1573.
- Rosener M, Dichgans J. Severe combined degeneration of the spinal cord after nitrous oxide anaesthesia in a vegetarian. *J Neurol Neurosurg Psychiatry.* 1996;60:354.
- Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B<sub>12</sub>. *Scan J Gastroenterol.* 1982;17:129-131.
- Scalabrino G, Tredici G, Buccellato FR, et al. Further evidence for the involvement of epidermal growth factor in the signaling pathway of vitamin B<sub>12</sub> (cobalamin) in the rat central nervous system. *J Neuropathol Exp Neurol.* 2000;59:808-814.
- Selhub J, Morris MS, Jacques PF. In vitamin B<sub>12</sub> deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. *Proc Natl Acad Sci USA.* 2007;104(50):19995-20000.
- Stubbe J. Binding site of nature's most beautiful cofactor. *Science.* 1994;266:1663-1664.
- Sumner AE, Chin MM, Abraham JL, et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B<sub>12</sub> deficiency after gastric surgery. *Ann Intern Med.* 1996;124:469-476.
- van Asselt DZ, Blom HJ, Zuiderent R, et al. Clinical significance of low cobalamin levels in older hospital patients. *Neth J Med.* 2000;57:41-49.
- Vogiatzoglou A, Refsum H, Johnston C, et al. Vitamin B<sub>12</sub> status and rate of brain volume loss in community-dwelling elderly. *Neurology.* 2008;71(11):826-832.

Warren MJ. Finding the final pieces of the vitamin B<sub>12</sub> biosynthetic jigsaw. *Proc Natl Acad Sci USA*. 2006;103(13):4799-4800.

Watanabe F, Katsura H, Takenaka S, et al. Pseudovitamin B<sub>12</sub> is the predominant cobamide of an algal health food, spirulina tablets. *J Agric Food Chem*. 1999;47:4736-4741.

Weir DG, Scott JM. Brain function in the elderly: role of vitamin B<sub>12</sub> and folate. *Br Med Bull*. 1999;55:669-682.

Weir DG, Scott JM. Vitamin B<sub>12</sub> "Cobalamin." In: Shils ME, Olson JA, Shike M, Ross AC, eds. *Modern Nutrition in Health and Disease*. 9th ed. Baltimore, MD; Williams and Wilkins; 1999:447-458.

Wolters M, Ströhle A, Hahn A. Cobalamin: a critical vitamin in the elderly. *Prev Med*. 2004;39(6):1256-1266.

## Vitamin C

### DESCRIPTION

The term vitamin C applies to substances that possess antiscorbutic activity and includes two compounds and their salts: L-ascorbic acid, commonly called ascorbic acid, and L-dehydroascorbic acid. Ascorbic acid is the major dietary form of vitamin C. The terms vitamin C, ascorbic acid, L-ascorbic acid, L-ascorbate and ascorbate are commonly used interchangeably.

Vitamin C is a hexose derivative, similar in structure to the six-carbon sugar glucose. It is an essential nutrient for humans, and, as pointed out by Linus Pauling in 1970, "differs from other nutrients in that it is required in the diet by only a few species of animals—man, other primates, the guinea pig, an Indian fruit-eating bat, and the red-vented barbul and some related species of Passeriform birds." It is also an essential nutrient for Coho salmon, rainbow trout, carp and some insects. Most other animals, all higher plant species and probably all algal classes can synthesize vitamin C from glucose or other sugars. Molecules similar to ascorbic acid are made by some fungi but not by bacteria. All vitamin C requiring animals lack the enzyme L-gulano-gamma-lactone oxidase, the final step in the synthesis of ascorbic acid from glucose. Plants produce large amounts of ascorbic acid to facilitate resistance to the oxidative stresses associated with the myriad biotic and abiotic challenges inherent to photosynthesis.

The major deficiency syndrome of vitamin C is scurvy. Symptoms of scurvy include inflamed and bleeding gums, petechiae, ecchymosis, follicular hyperkeratosis, coiled hairs, perifollicular hemorrhages, impaired wound healing, dry eyes and mouth (Sjögren's syndrome), arthralgia, joint effusions, muscle weakness, myalgia, fatigue, depression, frequent infections, anemia, anorexia; diarrhea, and pulmo-

nary and kidney problems that can lead to coma and death. All systems of the body are affected by scurvy.

The antiscorbutic factor was isolated from the ox adrenal cortex in 1927 by the Hungarian biochemist and Nobel laureate Albert Szent-Györgyi and his colleagues, although at the time Szent-Györgyi didn't know that it was the antiscorbutic factor. In fact, his interest then was not in vitamins at all but in biological oxidation and reduction, and he was looking for reducing substances in extracts of the adrenal cortex. What was later to be known as ascorbic acid, Szent-Györgyi called "C XII" since it was the 12<sup>th</sup> substance prepared and examined in his work on tissue oxidation and the function of the adrenal cortex. He later discovered that C XII was indeed vitamin C, the antiscorbutic factor, that its empirical formula was C<sub>6</sub>H<sub>8</sub>O<sub>6</sub> and that the molecule was a carbohydrate, most likely a sugar derivative. He submitted a paper on his discovery, which he named Ignose (from "ignosco"—"I don't know" in Latin—and "-ose" to indicate that it was a member of the sugar family). However, the editor of the journal rejected that name and also the next one that Szent-Györgyi came up with, "Godnose." The editor suggested "hexuronic acid" to indicate that it had six carbons and was a sugar acid similar to glucuronic acid. Szent-Györgyi gave in and accepted that name, which shortly was to change to ascorbic acid. Szent-Györgyi actually didn't know the exact structure of ascorbic acid, which explains Ignose and Godnose. It was the chemist and also Nobel laureate Walter Haworth who actually deciphered the structure. Szent-Györgyi found a rich source of ascorbic acid in the fruit of the Hungarian red pepper or paprika (*Capsicum annum*). He also found some other interesting reducing agents in paprika. He called these substances vitamin P. They were the first flavonoids identified. In 1932, the American biochemist Glen King and his colleagues isolated ascorbic acid from lemon juice, which is where the vitamin C story first began. Well, actually lime juice, but close enough.

Many of the symptoms of scurvy, particularly those having to do with connective tissue, can be explained by the known biochemical roles of vitamin C, particularly its role as a cofactor for prolyl and lysyl hydroxylase, enzymes important in the formation of collagen. Collagen synthesized in the absence of ascorbic acid—as occurs in scurvy—cannot properly form fibers, resulting in blood-vessel fragility, among other defects. In the prolyl and lysyl hydroxylase reactions, as well as in most of the biochemical reactions ascorbic acid participates in, it acts as a reducing agent. In these reactions, the vitamin reduces ferric and cupric ions to their ferrous and cuprous states, forms which are required for the reactions to proceed.